FDA Approves Zepbound as First Medication for Obstructive Sleep Apnea in Adults with Obesity

The drug, which also promotes significant weight loss, offers a new treatment option for millions affected by the condition.

Zepbound, generically known as tirzepatide, has been approved by the FDA to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
Clinical trials showed that Zepbound reduced apnea episodes by up to two-thirds and led to remission of symptoms in nearly half of participants after one year.
Patients on Zepbound experienced significant weight loss, averaging 18-20% of body weight, further aiding in the treatment of OSA symptoms.
The approval marks the first drug-based treatment for OSA, which affects an estimated 20 million Americans with moderate-to-severe cases.
While Zepbound offers a convenient alternative to CPAP machines, experts suggest combining therapies for optimal outcomes.